The Experts below are selected from a list of 861 Experts worldwide ranked by ideXlab platform

H J Van Beekhuizen - One of the best experts on this subject based on the ideXlab platform.

Nour Sneige - One of the best experts on this subject based on the ideXlab platform.

  • Peritoneal Washing cytologic analysis of ovarian serous tumors of low malignant potential to detect Peritoneal implants and predict clinical outcome
    Cancer Cytopathology, 2012
    Co-Authors: Nour Sneige, John B Thomison, Anais Malpica, Yun Gong, Joe Ensor, Elvio G Silva
    Abstract:

    BACKGROUND: Patients with ovarian serous tumors of low malignant potential (OSLMP) who have Peritoneal implants, especially invasive implants, are at an increased risk of developing tumor recurrence. To the best of the authors' knowledge, the ability of Peritoneal Washing (PW) cytology to detect the presence and type of Peritoneal implants has not been adequately investigated, and its prognostic significance is unknown. METHODS: Records and PW specimens of 101 patients diagnosed with and treated for OSLMP between 1996 and 2010 at The University of Texas MD Anderson Cancer Center were retrospectively reviewed. Patients' staging biopsy findings were compared with the results of the authors' review of the PWs. Follow-up data were also analyzed. RESULTS: Of the 96 patients for whom staging biopsy results were available, 26 (27%) had Peritoneal implants (17 noninvasive and 9 invasive), 19 (20%) had endosalpingiosis, and 51 (53%) had negative findings. The PW specimens of 18 of the 26 patients (69%) with Peritoneal implants were positive for serous neoplasm, and a correlation was found between cytologic and histologic findings (P < .0001). The sensitivity, specificity, positive predictive value, and negative predictive value were 69%, 84%, 62%, and 88%, respectively. Four of 101 patients had disease recurrence; 3 of these patients had invasive implants and 1 patient had noninvasive implants. None of the patients who had negative staging biopsy findings or endosalpingiosis but did have PW specimens that were positive for serous neoplasm developed disease recurrence. CONCLUSIONS: PW cytology detects the presence of Peritoneal implants with moderate accuracy. However, long-term studies are needed to determine whether positive PW cytologic findings are an independent predictor of tumor recurrence. Cancer (Cancer Cytopathol) 2012;. © 2012 American Cancer Society.

  • Peritoneal Washing cytology in patients with brca1 or brca2 mutations undergoing risk reducing salpingo oophorectomies a 10 year experience and reappraisal of its clinical utility
    Gynecologic Oncology, 2012
    Co-Authors: Gene Landon, John Stewart, Michael T Deavers, Nour Sneige
    Abstract:

    Objective To evaluate the utility of Peritoneal Washing cytology (PWC) for detecting occult primary Peritoneal carcinoma in patients with BRCA1 or BRCA2 mutations, we reviewed PWCs obtained during risk-reducing salpingo-oophorectomy (RRSO) from 117 patients at our institution and correlated the results with surgical pathology findings.

  • Peritoneal Washing cytology in women diagnostic pitfalls and clues for correct diagnosis
    Diagnostic Cytopathology, 1992
    Co-Authors: Nour Sneige, V Christina M D Fanning
    Abstract:

    The significance of Peritoneal Washing cytology in the management of patients with gynecologic cancer is well established. Its microscopic evaluation, however, is not always straightforward. Previous studies have identified some of the conditions that may result in misinterpretation of cytologic results. This report reviews the literature and describes other sources of diagnostic difficulties and clues for correct diagnosis. In addition, an outline for distinguishing endosalpingiosis from borderline and well-differentiated serous carcinoma is proposed.

Jun Eul Hwang - One of the best experts on this subject based on the ideXlab platform.

  • observational study of Peritoneal Washing cytology positive gastric cancer without gross Peritoneal metastasis in patients who underwent radical d2 gastrectomy
    Scientific Reports, 2020
    Co-Authors: Hyunjeong Shim, Hyeonjong Kim, Seung Hyuk Lee, Woo Kyun Bae, Eu Chang Hwang, Sanghee Cho, Ikjoo Chung, Hyunjin Bang, Jun Eul Hwang
    Abstract:

    Background The clinical features and therapeutic strategies for gastric cancer with positive Peritoneal Washing cytology but without visible gross Peritoneal metastasis have not been defined. The aim of this study was to evaluate the effect and clinical prognostic value of postoperative chemotherapy in gastric cancer patients with positive Peritoneal Washing cytology without gross Peritoneal metastasis who underwent radical D2 gastrectomy in terms of disease-free survival (DFS) and overall survival (OS). Materials and Methods Intraoperative Peritoneal Washing cytology was performed in 285 patients who underwent radical D2 gastrectomy between April 2004 and May 2016. Of them, 88 patients with positive cytology but without gross Peritoneal metastasis were included in the study. In total, 64 patients received postoperative chemotherapy, whereas 24 patients underwent surgery only. Results Most gastric cancer patients with positive cytology without gross Peritoneal metastasis demonstrated pT4 and/or pN3 disease. Postoperative chemotherapy improved DFS and OS compared to surgery only in gastric cancer patients with positive cytology without gross Peritoneal metastasis (median DFS 11.63 vs. 6.98 months, p < 0.001; median OS 25.50 vs. 12.11 months, p < 0.001). In multivariate analyses of gastric cancer patients with positive cytology without gross Peritoneal metastasis, no chemotherapy was the strongest clinical factor for poorer DFS (hazard ratio [HR] 3.76, p < 0.001) or OS (HR 4.37, p < 0.001). Conclusion Postoperative chemotherapy improves the survival outcome compared to surgery alone in gastric cancer patients with positive Peritoneal Washing cytology but without visible gross Peritoneal metastasis who underwent radical D2 gastrectomy.

  • observational study of the Peritoneal Washing cytology positive gastric cancer without gross Peritoneal metastasis underwent radical d2 gastrectomy
    Annals of Oncology, 2019
    Co-Authors: Jun Eul Hwang, Hyunjeong Shim, Hyeonjong Kim, Woo Kyun Bae, Sungyong Cho, In Jae Chung
    Abstract:

    Abstract Background Clinical features and therapeutic strategies for Peritoneal Washing cytology- positive (CY+) gastric cancer without gross Peritoneal metastasis have not yet been defined. The aim of the study was to evaluate the clinical prognostic impacts of postoperative chemotherapy for treating gastric cancer patients with CY+ without Peritoneal metastasis. Methods Intraoperative Peritoneal Washing cytology was performed in 285 patients who underwent curative D2 gastrectomy between April 2004 and May 2016. Of them, 88 patients with CY+ without Peritoneal metastasis were included in the study. 64 patients received postoperative chemotherapy, whereas 24 patients underwent surgery only. We combined CY + 64 patients who received postoperative chemotherapy with another cohort of stage II/III gastric cancer patients (n = 819) who received adjuvant chemotherapy, for survival comparison. Results The Disease-free survival (DFS) and overall survival (OS) curves were well separated according to stage and CY+ in combined cohort (both, P  Conclusions The prognosis of gastric cancer with CY+ without gross Peritoneal metastasis is somewhat different from gastric cancer with overt Peritoneal metastasis, and postoperative chemotherapy improves survival outcome in this patient group. Legal entity responsible for the study The authors. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest.

F Blok - One of the best experts on this subject based on the ideXlab platform.

Hyunjeong Shim - One of the best experts on this subject based on the ideXlab platform.

  • observational study of Peritoneal Washing cytology positive gastric cancer without gross Peritoneal metastasis in patients who underwent radical d2 gastrectomy
    Scientific Reports, 2020
    Co-Authors: Hyunjeong Shim, Hyeonjong Kim, Seung Hyuk Lee, Woo Kyun Bae, Eu Chang Hwang, Sanghee Cho, Ikjoo Chung, Hyunjin Bang, Jun Eul Hwang
    Abstract:

    Background The clinical features and therapeutic strategies for gastric cancer with positive Peritoneal Washing cytology but without visible gross Peritoneal metastasis have not been defined. The aim of this study was to evaluate the effect and clinical prognostic value of postoperative chemotherapy in gastric cancer patients with positive Peritoneal Washing cytology without gross Peritoneal metastasis who underwent radical D2 gastrectomy in terms of disease-free survival (DFS) and overall survival (OS). Materials and Methods Intraoperative Peritoneal Washing cytology was performed in 285 patients who underwent radical D2 gastrectomy between April 2004 and May 2016. Of them, 88 patients with positive cytology but without gross Peritoneal metastasis were included in the study. In total, 64 patients received postoperative chemotherapy, whereas 24 patients underwent surgery only. Results Most gastric cancer patients with positive cytology without gross Peritoneal metastasis demonstrated pT4 and/or pN3 disease. Postoperative chemotherapy improved DFS and OS compared to surgery only in gastric cancer patients with positive cytology without gross Peritoneal metastasis (median DFS 11.63 vs. 6.98 months, p < 0.001; median OS 25.50 vs. 12.11 months, p < 0.001). In multivariate analyses of gastric cancer patients with positive cytology without gross Peritoneal metastasis, no chemotherapy was the strongest clinical factor for poorer DFS (hazard ratio [HR] 3.76, p < 0.001) or OS (HR 4.37, p < 0.001). Conclusion Postoperative chemotherapy improves the survival outcome compared to surgery alone in gastric cancer patients with positive Peritoneal Washing cytology but without visible gross Peritoneal metastasis who underwent radical D2 gastrectomy.

  • observational study of the Peritoneal Washing cytology positive gastric cancer without gross Peritoneal metastasis underwent radical d2 gastrectomy
    Annals of Oncology, 2019
    Co-Authors: Jun Eul Hwang, Hyunjeong Shim, Hyeonjong Kim, Woo Kyun Bae, Sungyong Cho, In Jae Chung
    Abstract:

    Abstract Background Clinical features and therapeutic strategies for Peritoneal Washing cytology- positive (CY+) gastric cancer without gross Peritoneal metastasis have not yet been defined. The aim of the study was to evaluate the clinical prognostic impacts of postoperative chemotherapy for treating gastric cancer patients with CY+ without Peritoneal metastasis. Methods Intraoperative Peritoneal Washing cytology was performed in 285 patients who underwent curative D2 gastrectomy between April 2004 and May 2016. Of them, 88 patients with CY+ without Peritoneal metastasis were included in the study. 64 patients received postoperative chemotherapy, whereas 24 patients underwent surgery only. We combined CY + 64 patients who received postoperative chemotherapy with another cohort of stage II/III gastric cancer patients (n = 819) who received adjuvant chemotherapy, for survival comparison. Results The Disease-free survival (DFS) and overall survival (OS) curves were well separated according to stage and CY+ in combined cohort (both, P  Conclusions The prognosis of gastric cancer with CY+ without gross Peritoneal metastasis is somewhat different from gastric cancer with overt Peritoneal metastasis, and postoperative chemotherapy improves survival outcome in this patient group. Legal entity responsible for the study The authors. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest.